Back to Article List

Health claim evaluation on grape seed extract and maintenance of normal blood pressure published by EFSA

European Union

Aug 18, 2021

On August 9, EFSA published  an evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: MegaNatural‐BP grape seed extract and maintenance of normal blood pressure.

The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. MegaNatural®‐BP, a grape seed extract standardised for total phenolics, gallic acid and the catechin and epicatechin content, is sufficiently characterised. The proposed claimed effect, maintenance of normal blood pressure (BP), is a beneficial physiological effect. Among the two human intervention studies provided from which conclusions could be drawn, one showed an effect of MegaNatural®‐BP (300 mg/day) on BP in adults with normal and high normal BP when consumed daily for 6 weeks, whereas the second study did not show an effect of MegaNatural®‐BP at the same daily dose consumed for 8 weeks in adults with normal and high normal blood pressure or stage 1 hypertension. The evidence provided did not establish a plausible mechanism by which the food could exert the claimed effect in vivo in humans. The evidence provided is insufficient to establish a cause and effect relationship between the consumption of MegaNatural®‐BP and maintenance of normal blood pressure.

For further information (in English), click on the Link

Subscribe to our newsletter

The best industry insight in your mailbox